AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental weight-loss pill delivered encouraging mid-stage trial results, prompting investors and analysts to reassess whether the British drugmaker can challenge the dominance of Novo Nordisk and Eli Lilly.
The company said on Monday that patients receiving the highest dose of its once-daily obesity pill, elecoglipron, lost 11.8% of their body weight after 36 weeks of treatment.
After 26 weeks, patients had already achieved an average weight reduction of 10.5%, with weight loss continuing throughout the study period.
The results, presented at the American Diabetes Association meeting in New Orleans, provide the most detailed look yet at a drug AstraZeneca hopes could become a major growth driver in one of the pharmaceutical industry’s fastest-growing markets.
Trial results compare favourably with rivals
AstraZeneca first disclosed in February that the study had met its primary endpoints and would advance into late-stage testing, though it had not released detailed efficacy data at the time.
The latest results suggest elecoglipron could be competitive with oral obesity treatments being developed by industry leaders.
Novo Nordisk’s oral version of Wegovy has demonstrated around 14% weight loss in clinical studies, while Eli Lilly’s experimental pill Foundayo produced approximately 12% weight loss in a late-stage trial.
Although AstraZeneca’s candidate trails the strongest weight-loss data generated by injectable treatments, analysts say the results were stronger than many investors had anticipated.
Sharon Barr, AstraZeneca’s executive vice president for biopharmaceuticals research and development, said the findings demonstrated a competitive profile for elecoglipron and reinforced its potential to become a “blockbuster asset”.
She added that the company views the drug as a backbone for future combination therapies aimed at addressing obesity and related metabolic diseases.
Ambitious late-stage program planned
Buoyed by the encouraging data, AstraZeneca plans to launch an extensive phase 3 development program during the second half of the year.
The company intends to evaluate elecoglipron both as a standalone treatment and in combination with its diabetes medicine Farxiga.
Studies will include patients living with obesity as well as overweight individuals, regardless of whether they have type 2 diabetes.
Beyond weight loss, AstraZeneca also plans to investigate the drug’s potential role in treating heart failure and chronic kidney disease, reflecting growing interest across the pharmaceutical industry in the broader cardiometabolic benefits of obesity medicines.
Obesity drug success is a positive surprise
Analysts at Jefferies said the trial results exceeded expectations and strengthened AstraZeneca’s ability to compete in an increasingly crowded field.
The brokerage noted that the company is pursuing one of the most comprehensive obesity development programs among large pharmaceutical companies and could benefit from opportunities that are not yet fully reflected in market expectations.
“AstraZeneca is the only company for which obesity offers room for positive surprises, given that it isn’t factored into consensus expectations,” Jefferies said.
The obesity treatment market has become one of the most closely watched areas in healthcare, with demand for weight-loss drugs continuing to surge globally.
According to the World Health Organization, more than one billion people worldwide are living with obesity, creating a vast potential market for pharmaceutical companies.
Ruben Dalfovo, investment strategist at Saxo, said the market has become too large to be dominated by only two companies.
“The obesity market is now too large for only two companies,” Dalfovo said.
He noted that AstraZeneca’s strategy differs from those of Novo Nordisk and Eli Lilly, focusing not only on weight-loss efficacy but also on combination therapies, cardiometabolic expertise, pricing flexibility, and its strong presence in emerging markets.
While AstraZeneca’s weight-loss data remain below the most impressive results achieved by injectable treatments, analysts believe the company’s broader healthcare portfolio could provide a meaningful competitive advantage.
For investors, the latest trial results suggest AstraZeneca may be developing into one of the more credible challengers to the current obesity market leaders.
With a large phase 3 program set to begin later this year, attention will now turn to whether elecoglipron can replicate its mid-stage success and secure a place in what is expected to become one of the pharmaceutical industry’s largest therapy categories.
The post AstraZeneca’s obesity drug shows promise as analysts see upside beyond consensus appeared first on Invezz
